Navigation Links
Sunpeaks Ventures Signs Advertising and Promotion Agreement With Another Major Sports Team - Clotamin To Be Sold at All Walgreens Locations Throughout Arizona
Date:4/13/2012

SILVER SPRING, Md., April 13, 2012 /PRNewswire/ -- Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" or "Sunpeaks Ventures") and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS") are pleased to announce that HDS has entered into an advertising and promotion agreement ("Agreement") with a major pro sports team based in the state of Arizona (the "Team") for the marketing of Clotamin.  The Agreement is part of new marketing initiatives to promote and launch Clotamin in 240 Walgreens throughout Arizona.

Under terms of the Agreement, HDS, in conjunction with Walgreens, will have the right to make use of the Team name and logo in connection with an in-store Clotamin promotion, including the prominent placement of counter point-of-sale (POS) displays in all Walgreens locations in the state of Arizona for the duration of the promotion – approximately five months, beginning on June 1, 2012. 

During the consumer promotion and advertising program, Clotamin will be featured at Team home games on signage and other marketing elements throughout the University of Phoenix Stadium in Glendale, Arizona.  Team fans will be encouraged to visit their local Walgreens location, pick-up an entry form at the Team vendor display, and register for the opportunity to experience a Team home game in the comfort of an exclusive private box.  One lucky winner each month (4 total) will receive a private box for a Team home game, including game tickets, VIP parking passes, and a food and beverage package for 16 guests.  Also included in the exclusive prize package experience is special personal appearance by the Team mascot/cheerleaders and 16 team gift bags. 

"Similar to our pro sports team deal to market Clotamin with Walgreens in Oregon, this new agreement in Arizona is designed to leverage our advertising capabilities to grow awareness and acceptance of Clotamin with strong endorsements and strategic sponsorships," stated Mackie A. Barch, CEO of Sunpeaks Ventures. "The marketing combination of pharmacy powerhouse Walgreens and a highly-recognizable pro sports team is designed to allow us to quickly introduce Clotamin to a statewide audience of loyal customers and fans.  We look forward to working closely with Walgreens and the Team to make this a successful product launch and an unforgettable experience for our contest winners."

About Sunpeaks Ventures, Inc.

Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market.   HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.

For additional information, please visit www.sunpeaksventures.com.

Contact: Financial Insights 888-248-8491 or info@sunpeaksventures.com

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements.  These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Sunpeaks Ventures' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements.  The risks, uncertainties and other factors are more fully discussed in Sunpeaks Ventures' filings with the U.S. Securities and Exchange Commission.  All forward-looking statements attributable to Sunpeaks Ventures herein are expressly qualified in their entirety by the above-mentioned cautionary statement.  Sunpeaks Ventures disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.


'/>"/>
SOURCE Sunpeaks Ventures, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sunpeaks Ventures Enters Agreement with UK Based Healthcare Firm to Introduce Clotamin to UK and European Union Countries
2. Sunpeaks Ventures Announces Letter of Intent to Export Clotamin to Top Russian Pharmacies
3. Sunpeaks Ventures Inks Sponsorship and Marketing Agreement with Major Sports Team, Clotamin To Be Sold at Walgreens Locations Throughout Oregon and Southern Washington
4. Sunpeaks Ventures Announces Agreement with Asian American Convenience Store Association Partners to Sell Clotamin in 1,200 Stores
5. Sunpeaks Ventures Announces Agreement with Albeck Financial Services
6. Sunpeaks Ventures Announces Clotamin to Be Sold at Winn-Dixie Locations in South Florida
7. Sunpeaks Ventures Announces Clotamin to be Sold at Bravo Supermarkets in South Florida
8. Sunpeaks Ventures to Participate in ECRM Conference and Expo
9. Sunpeaks Ventures Announces Clotamin to be Sold at Navarro Discount Pharmacies
10. Sunpeaks Ventures Announces Clotamin available on Walgreens.com
11. Sunpeaks Ventures Enters $45 Billion Specialty Drug Distribution Sector
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... YORK , Feb. 23, 2017  The ... 330.6 million by 2021 from USD 275.9 million ... Read the full report: http://www.reportlinker.com/p04718602-summary/view-report.html ... increasing spending on pharmaceutical R&D, and growth in ... driving the market growth for particle counters. On ...
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... Price Analysis and Strategies - 2016" report to their offering. ... The latest ... provides drug pricing data and benchmarks in the global Autism Spectrum ... What are the key drugs marketed for Autism ...
(Date:2/23/2017)... CITY, Calif., Feb. 23, 2017 Nevro Corp. (NYSE: ... evidence-based solutions for the treatment of chronic pain, today reported ... December 31, 2016. 2016 Accomplishment & Highlights: ... full year 2016, an increase of 228% as reported, over ... for 2016, an increase of 612% over the prior year ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... WHAT: ... networking and recognition opportunities as well as advocacy for the state and region‘s ... on February 23. The Council's Innovation Forecast event highlights innovation throughout the ...
(Date:2/24/2017)... ... , ... With millions of Americans and people worldwide struggling ... are aware of our options and are empowered with strength and information throughout ... its newest edition of "Vision and Hearing" in USA Today, that will educate ...
(Date:2/24/2017)... , ... February 24, 2017 , ... Yisrayl Hawkins, Pastor ... on Bible Prophecy concerning this present generation. Yisrayl makes an astounding statement when ... generation. He explains that the Bible details the current times so plainly that ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations to ... Elite division on February 12th. Ms. Esparza qualified into this prestigious status ... competition held in Las Vegas, Nevada. Frida is one of approximately 25 gymnasts ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... the La Gorce Country Club in Miami Beach to host its Swirl: Miami ...
Breaking Medicine News(10 mins):